Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea

Won Suk Choi, Ji Yun Noh, Jacob Lee, Jun Yong Choi, Jin-Soo Lee, Moo Soo Kim, Hee Soo Kim, Joon Bang, Nathalie Lavis, Woo Joo Kim, Won Suk Choi, Ji Yun Noh, Jacob Lee, Jun Yong Choi, Jin-Soo Lee, Moo Soo Kim, Hee Soo Kim, Joon Bang, Nathalie Lavis, Woo Joo Kim

Abstract

VaxigripTetra® (Sanofi Pasteur, Lyon, France) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) containing two B-lineage strains approved in the European Union and Taiwan in 2016 for individuals ≥ 3 years of age. Here, we describe an observer-blind, randomized, controlled, multicenter trial study evaluating the immunogenicity and safety of the Northern Hemisphere 2015-2016 formulations of IIV4 and the licensed split-virion trivalent inactivated influenza vaccine (IIV3) in the Republic of Korea (ClinicalTrials.gov no. NCT02550197). The study included 300 Korean adults 18-60 years of age randomized 2:1 to receive a single injection of IIV4 or IIV3. For each of the four vaccine strains in IIV4, 21 days after vaccination, geometric mean post-/pre-vaccination ratios of hemagglutination inhibition titers were ≥ 3.97. Seroconversion/significant increases rates were ≥ 40% for all but the A/H1N1 strain, for which the rate was 39.7%. Results were similar for the three strains in IIV3. For the additional B-lineage strain not in IIV3 (Victoria), hemagglutination inhibition antibody titers were higher for IIV4 than for IIV3. Solicited reactions and adverse events were similar between IIV4 and IIV3, and no serious adverse events or new safety signals were detected. These results confirm the robust immunogenicity and acceptable safety of IIV4 in adults 18-60 years of age and show that including a second B-lineage strain should provide broader protection against B-strain influenza without affecting vaccine safety or the immunogenicity of other three vaccine strains.

Keywords: Republic of Korea; adults; inactivated influenza vaccine; quadrivalent influenza vaccine.

References

    1. Park M, Wu P, Goldstein E, Kim WJ, Cowling BJ. Influenza-Associated Excess Mortality in South Korea. Am J Prev Med. 2016;50:e111-9. doi:10.1016/j.amepre.2015.09.028.
    1. Suh M, Kang DR, Lee DH, Choi YJ, Tchoe B, Nam CM, Kim HJ, Lee JK, Jun BY, Youm Y, et al. . Socioeconomic burden of influenza in the Republic of Korea, 2007–2010. PLoS One. 2013;8:e84121. doi:10.1371/journal.pone.0084121.
    1. Kim YT. Current situation and elimination plan of influenza. J Korean Med Assoc. 2004;47:1116-28. doi:10.5124/jkma.2004.47.11.1116.
    1. Oh MD, Lee JK. Milestones in history of adult vaccination in Korea. Clin Exp Vaccine Res. 2012;1:9-17. doi:10.7774/cevr.2012.1.1.9. doi:10.7774/cevr.2012.1.1.9.
    1. Yang HJ, Cho SI. Influenza vaccination coverage among adults in Korea: 2008–2009 to 2011–2012 seasons. Int J Environ Res Public Health. 2014;11:12162-73. doi:10.3390/ijerph111212162.
    1. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12:1085-94. doi:10.1586/14760584.2013.824709. PMID:24024871.
    1. Centers for Disease Control and Prevention Past Weekly Surveillance Reports. 2017. [accessed 2017May9]. .
    1. Public Health Agency of Canada Statement on seasonal influenza vaccine for 2014–2015. 2014. [accessed 2016August29]. .
    1. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-8. doi:10.4161/hv.8.1.17623.
    1. Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31:5572-8. doi:10.1016/j.vaccine.2013.08.069. PMID:24016810
    1. Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, et al. . Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 2015;33:2485-92. doi:10.1016/j.vaccine.2015.03.065.
    1. Pepin S, Szymanski H, Rochin Kobashi IA, Villagomez Martinez S, Gonzalez Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, et al. . Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study. Hum Vaccin Immunother. 2016;12(12):3072-8. doi:10.1080/21645515.2016.1212143.
    1. Committee for Medicinal Products for Human Use Note for guidance on harmonisation of requirements for influenza vaccines. 1997. [accessed 2017May9]. .
    1. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31:745-51. doi:10.1097/INF.0b013e31825687b0.
    1. Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky F, Mallory RM. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*. Influenza Other Respir Viruses. 2013;7:1142-50. doi:10.1111/irv.12027.
    1. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770-6. doi:10.1016/j.vaccine.2012.11.074.
    1. International Conference on Harmonization Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1994. [accessed 2017May9]. .

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe